A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Xanomeline and Trospium (Cobenfy)

Cholinergic Muscarinic Agonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2024-09-27
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$30.30/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$30.32
Across all dosage forms in distribution.
Highest NADAC
$30.35
Range is tight.
Plans with PA
928 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Xanomeline and Trospium used for?

Xanomeline and Trospium is a Cholinergic Muscarinic Agonist medication tracked in Medicare Part D.

Is there a generic for Xanomeline and Trospium?

No. Xanomeline and Trospium is brand-only with no generic equivalents currently in market.

How much does my plan pay for Xanomeline and Trospium?

Across 329 Part D plans, Xanomeline and Trospium averages $30.32/unit (NADAC). Lowest available: $30.30/unit. Highest in distribution: $30.35/unit.

Is Xanomeline and Trospium on the FDA shortage list?

No. Xanomeline and Trospium is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Cholinergic Muscarinic Agonist1 alternative in D1
01
Bethanechol
Cholinergic Muscarinic Agonist
$0.102Lowest NADAC
4Generic mfrs
$15.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.